Innovation
in Nucleic Acid Therapeutics for Human Health

OLX201

  • HOME
  • R & D
  • OliX Pipeline
  • OLX201

Idiopathic Pulmonary Fibrosis (IPF)

특발성 폐 섬유화
  • Scarring of lung tissue is a chronic, irreversible fatal disease
  • Symptoms : chronic dry, hacking cough, fatigue and weakness, discomfort in the chest, loss of appetite, unexplained weight loss
  • Currently, there is no cost-effective therapeutics for the IPF

Market Potential

  • IPF patients are estimated about 80,000~110,000 in EU (Source : European IPF Charter)
  • Approximately 30,000-35,000 new patients emerging every year
  • Annual Potential IPF market : $900M in 2015
    By 2025, expected to grow to $3.2B
    (Source : GlobalData Healthcare 2016)

Government Funding

  • A*STAR(Singapore)-KHIDI(Korea) Joint Grant Call : $1.8M / 3 years (2014.10~2017.09)
    * KHIDI : Korea Health Industry Development Institute (www.khidi.or.kr)

Development Status

  • Outstanding efficacy identified from animal models (thesis to be published)
  • Overseas phase 1 clinical trial planned to take place in 2020